AC Immune SA
General ticker "ACIU" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $250.8M (TTM average)
AC Immune SA follows the US Stock Market performance with the rate: 43.5%.
Estimated limits based on current volatility of 4.1%: low 2.68$, high 2.91$
Factors to consider:
- Total employees count: 67 as of 2016
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.82$, 3.89$]
- 2025-12-31 to 2026-12-31 estimated range: [1.52$, 3.33$]
Financial Metrics affecting the ACIU estimates:
- Positive: with PPE of -4.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Operating cash flow per share per price, % of 27.17 > 13.24
- Positive: 41.86 < Shareholder equity ratio, % of 48.62 <= 63.39
- Negative: negative Industry operating cash flow (median)
Short-term ACIU quotes
Long-term ACIU plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | CHF3.94MM | CHF14.80MM | CHF27.31MM |
| Operating Expenses | CHF74.78MM | CHF68.42MM | CHF79.69MM |
| Operating Income | CHF-70.85MM | CHF-53.62MM | CHF-52.38MM |
| Non-Operating Income | CHF0.11MM | CHF-0.60MM | CHF1.47MM |
| Interest Expense | CHF0.35MM | CHF0.18MM | CHF0.13MM |
| R&D Expense | CHF60.34MM | CHF54.61MM | CHF62.57MM |
| Income(Loss) | CHF-70.74MM | CHF-54.22MM | CHF-50.91MM |
| Taxes | CHF0.01MM | CHF0.01MM | CHF0.00MM |
| Profit(Loss)* | CHF-70.75MM | CHF-54.23MM | CHF-50.92MM |
| Stockholders Equity | CHF168.99MM | CHF160.64MM | CHF112.27MM |
| Assets | CHF185.94MM | CHF182.81MM | CHF230.91MM |
| Operating Cash Flow | CHF-73.57MM | CHF-60.41MM | CHF65.84MM |
| Capital expenditure | CHF1.24MM | CHF0.80MM | CHF0.58MM |
| Investing Cash Flow | CHF23.76MM | CHF65.64MM | CHF-105.29MM |
| Financing Cash Flow | CHF-1.35MM | CHF43.25MM | CHF-1.12MM |
| Earnings Per Share** | CHF-0.85 | CHF-0.64 | CHF-0.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.